Bradykinin‐antagonists: Therapeutic perspectives

J. E. Taylor, F.V. DeFeudis, J. P. Moreau

Drug Development Research · 1989 · 34 citations · 29 references

DOIFull text

Open access

Concepts

Abstract

Abstract In vitro and in vivo studies of the actions of various antagonists and agonists of bradykinin (BK) B 1 and B 2 receptors have been reviewed and analyzed. It seems apparent that certain B 2 ‐antagonists, such as [Thi 5,8 ,D‐Phe 7 ]‐BK and D‐Arg 0 ‐[Hyp 3 ,Thi 5,8 ,D‐Phe 7 ]‐BK will serve as valuable model substances for developing new anti‐inflammatory/analgesic drugs. Further development of B 1 ‐antagonists, based on modifications of the structure of des‐Arg 9 ,[Leu 8 ]‐BK, or combined B 1 /B 2 ‐antagonists might be useful in controlling disease states involving chronic tissue injury and/or prolonged vasopasm.

References

29